Ribomic Inc. (TYO:4591)
55.00
-1.00 (-1.79%)
Nov 18, 2026, 11:06 AM JST
Ribomic Revenue
Ribomic had revenue of 11.50M JPY in the quarter ending September 30, 2026. This brings the company's total for the last twelve months to 19.00M. In the fiscal year ending March 31, 2026, Ribomic had annual revenue of 3.00M with 50.00% growth. That makes Ribomic the 45,952nd largest company in the world by revenue and 3,874th in Japan.
Revenue (ttm)
19.00M
Revenue Growth
+50.00%
P/S Ratio
161.46
Revenue / Employee
n/a
Employees
25
Market Cap
3.12B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 3.00M | 1.00M | 50.00% |
| Mar 31, 2025 | 2.00M | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | 65.00M | -15.00M | -18.75% |
| Mar 31, 2022 | 80.00M | -11.00M | -12.09% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 14.02B |
| Kohjin Bio | 4.38B |
| Human Metabolome Technologies | 1.48B |
| MEDINET | 998.00M |
| SUSMED,Inc. | 679.00M |
| PRISM BioLab Co.,LTD | 518.00M |
| Kringle Pharma | 442.00M |
| D. Western Therapeutics Institute | 140.90M |